Marcain (Epinephrine, Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine blocks voltage‑gated sodium channels on nerve fibers, preventing the initiation and propagation of action potentials. This inhibition stops pain signal transmission. Epinephrine added to the formulation causes vasoconstriction, reducing systemic absorption and extending the anesthetic effect.

The specific dose of Marcain is determined by the prescribing clinician based on the type of procedure, patient weight, age, and clinical condition. Healthcare professionals calculate the appropriate volume and concentration to achieve effective anesthesia while staying within safety limits.

Safety data for Marcain in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Clinicians must assess each case individually and follow local regulatory guidance.

To request Marcain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with shorter‑acting agents such as lidocaine, bupivacaine in Marcain offers a longer duration of anesthesia, making it suitable for prolonged procedures. The addition of epinephrine further extends its effect and reduces systemic absorption, whereas plain bupivacaine formulations lack this vasoconstrictive benefit.

Marcain should be stored below 25 °C in its original packaging, protected from light and moisture. Do not freeze the product. Maintaining the recommended temperature helps preserve potency and sterility of the injectable solution.

Marcain is administered by a qualified healthcare professional via injection. It can be delivered epidurally for regional block, infiltrated directly into tissue for local anesthesia, or used for peripheral nerve blocks, following aseptic technique and appropriate dosing guidelines.

The most serious risks include cardiovascular toxicity such as arrhythmias or cardiac arrest, and central nervous system toxicity leading to seizures or respiratory depression. Prompt recognition and supportive management are essential if signs of systemic toxicity appear.

Marcain is contraindicated in patients with known hypersensitivity to amide‑type local anesthetics or epinephrine, and should be avoided in individuals with severe cardiac conduction disorders, uncontrolled hypertension, or certain neurological conditions where local anesthetic toxicity risk is heightened.